潜在绝育治疗前为生育力保存采集的人类青春期前睾丸组织中精原细胞数量
本研究评估化疗暴露或原发诊断是否影响青春期前男孩睾丸组织中的精原细胞数量,发现接受烷化剂治疗或羟基脲治疗镰状细胞病的男孩精原细胞数量显著减少,而接受非烷化剂治疗者的精原细胞数量与正常对照及参考值相当。
要点
- 接受烷化剂治疗的男孩平均精原细胞数/横切面小管为0.2±0.3(n=6),显著低于非烷化剂暴露组(1.7±1.0,n=8,P=0.003)。
- 镰状细胞病接受羟基脲治疗的男孩平均精原细胞数/横切面小管为0.3±0.6(n=6),显著低于生物样本库对照组(4.1±4.6,n=14,P=0.008)。
- 非烷化剂暴露组与生物样本库对照组的平均精原细胞数均在近期发表的正常参考值范围内。
核心结论
- 青春期前男孩接受烷化剂治疗或羟基脲治疗镰状细胞病后,睾丸精原细胞数量显著减少;接受非烷化剂治疗者的精原细胞数量与正常对照及参考值相当。
研究设计与样本
- 研究分析了2014年至2017年间NORDFERTIL研究中32例连续男孩患者(年龄6.3±3.8岁,均值±标准差)的睾丸组织石蜡切片,并纳入14例来自内部生物样本库的对照样本(男孩年龄5.6±5.0岁,均值±标准差)。
- 患者来自瑞典、芬兰和冰岛,面临与极高不孕风险相关的治疗;排除标准为睾丸体积>10 ml及高出血或感染风险。
- 18例患者诊断为恶性肿瘤,14例为非恶性诊断;20例在化疗后1-45天进行睾丸活检,12例未接受任何化疗。
- 精原细胞数量通过形态学和免疫组化分析评估,以每个横切面小管中的精原细胞数(S/T)表示。
- 对照样本来自卡罗林斯卡大学医院病理科内部生物样本库,并参考了近期发表的Meta分析提供的参考值。
主要发现
- 接受烷化剂治疗的男孩平均S/T为0.2±0.3(n=6),显著低于非烷化剂暴露组(1.7±1.0,n=8)和生物样本库对照组(4.1±4.6,n=14),P值分别为0.003和0.008。
- 镰状细胞病接受羟基脲治疗的男孩平均S/T为0.3±0.6(n=6),显著低于非烷化剂暴露组和生物样本库对照组,P值分别为0.003和0.008。
- 非烷化剂暴露组和生物样本库对照组的平均S/T值均在近期发表的正常参考值范围内。
关键数值与推荐
- 接受烷化剂治疗的男孩平均S/T为0.2±0.3(n=6),显著低于非烷化剂暴露组(1.7±1.0,n=8,P=0.003)和生物样本库对照组(4.1±4.6,n=14,P=0.008)。
- 镰状细胞病接受羟基脲治疗的男孩平均S/T为0.3±0.6(n=6),显著低于非烷化剂暴露组(1.7±1.0,n=8,P=0.003)和生物样本库对照组(4.1±4.6,n=14,P=0.008)。
- 非烷化剂暴露组(1.7±1.0,n=8)和生物样本库对照组(4.1±4.6,n=14)的平均S/T值均在近期发表的正常参考值范围内。
临床怎么用
- 作者认为,对于有生育力保存指征的青春期前男孩,应在开始烷化剂化疗前获取睾丸组织。
- 作者认为,对于接受羟基脲治疗的镰状细胞病男孩,这种生育力保存方法可能不可行。
局限性
- 正常睾丸组织样本来自卡罗林斯卡大学医院内部生物样本库,样本若未报告睾丸病理则被视为正常并纳入研究。
- 生物样本库中纳入患者的既往药物治疗详细信息和睾丸体积数据不可获得。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does chemotherapy exposure (with or without alkylating agents) or primary diagnosis affect spermatogonial quantity in human prepubertal testicular tissue? SUMMARY ANSWER: Spermatogonial quantity is significantly reduced in testes of prepubertal boys treated with alkylating agent therapies or with hydroxyurea for sickle cell disease. WHAT IS KNOWN ALREADY: Cryopreservation of spermatogonial stem cells, followed by transplantation into the testis after treatment, is a proposed clinical option for fertility restoration in children. The key clinical consideration behind this approach is a sufficient quantity of healthy cryopreserved spermatogonia. However, since most boys with malignancies start therapy with agents that are not potentially sterilizing, they will have already received some chemotherapy before testicular tissue cryopreservation is considered. STUDY DESIGN, SIZE, DURATION: We examined histological sections of prepubertal testicular tissue to elucidate whether chemotherapy exposure or primary diagnosis affects spermatogonial quantity. Quantity of spermatogonia per transverse tubular cross-section (S/T) was assessed in relation to treatment characteristics and normative reference values in histological sections of paraffin embedded testicular tissue samples collected from 32 consecutive boy patients (aged 6.3 ± 3.8 [mean ± SD] years) between 2014 and 2017, as part of the NORDFERTIL study, and in 14 control samples (from boys aged 5.6 ± 5.0 [mean ± SD] years) from an internal biobank. PARTICIPANTS/MATERIALS, SETTING, METHODS: Prepubertal boys in Sweden, Finland and Iceland who were facing treatments associated with a very high risk of infertility, were offered the experimental procedure of testicular cryopreservation. Exclusion criteria were testicular volumes >10 ml and high bleeding or infection risk. There were 18 patients with a diagnosis of malignancy and 14 patients a non-malignant diagnosis. While 20 patients had the testicular biopsy performed 1-45 days after chemotherapy, 12 patients had not received any chemotherapy. In addition, 14 testicular tissue samples of patients with no reported testicular pathology, obtained from the internal biobank of the Department of Pathology at Karolinska University Hospital, were included as control samples in addition to reference values obtained from a recently published meta-analysis. The quantity of spermatogonia was assessed by both morphological and immunohistochemical analysis. MAIN RESULTS AND THE ROLE OF CHANCE: The main finding was a significant reduction in spermatogonial cell counts in boys treated with alkylating agents or with hydroxyurea for sickle cell disease. The mean S/T values in boys exposed to alkylating agents (0.2 ± 0.3, n = 6) or in boys with sickle cell disease and exposed to hydroxyurea (0.3 ± 0.6, n = 6) were significantly lower (P = 0.003 and P = 0.008, respectively) than in a group exposed to non-alkylating agents or in biobank control samples (1.7 ± 1.0, n = 8 and 4.1 ± 4.6, n = 14, respectively). The mean S/T values of the testicular tissue samples included in the biobank control group and the patient group exposed to non-alkylating agents were within recently published normative reference values. LIMITATIONS, REASONS FOR CAUTION: Normal testicular tissue samples included in this study were obtained from the internal biobank of Karolinska University Hospital. Samples were considered normal and included in the study if no testicular pathology was reported in the analysed samples. However, detailed information regarding previous medical treatments and testicular volumes of patients included in this biobank were not available. WIDER IMPLICATIONS OF THE FINDINGS: This study summarizes, for the first time, spermatogonial quantity in a prepubertal patient cohort just before and after potentially sterilizing treatments. Boys facing cancer and cytotoxic therapies are regarded as the major group who will benefit from novel fertility preservation techniques. There are no previous reports correlating spermatogonial quantity to cumulative exposure to alkylating agents and anthracyclines (non-alkylating agents) and no information about the timing of cytotoxic exposures among this particular patient cohort. For prepubertal boys in whom fertility preservation is indicated, testicular tissue should be obtained before initiation of chemotherapy with alkylating agents, whilst for those with sickle cell disease and treated with hydroxyurea, this approach to fertility preservation may not be feasible. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by grants from The Swedish Childhood Cancer Foundation (PR2016-0124; TJ2016-0093; PR2015-0073, TJ2015-0046) (J.-B.S. and K.J.), the Jane and Dan Olssons Foundation (2016-33) (J.-B.S.), the Finnish Cancer Society (K.J.), the Foundation for Paediatric Research (J.-B.S.), Kronprinsessan Lovisas Förening För Barnasjukvård/ Stiftelsen Axel Tielmans Minnesfond, Samariten Foundation (J.-B.S.), the Väre Foundation for Paediatric Cancer Research (K.J.) and the Swedish Research Council (2012-6352) (O.S.). R.T.M. was supported by a Wellcome Trust Fellowship (09822). J.P.A.-L. and M.K. were supported by the ITN Marie Curie program 'Growsperm' (EU-FP7-PEOPLE-2013-ITN 603568). The authors declare no conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.
引用
- Stukenborg JB, Alves-Lopes JP, Kurek M, et al. Spermatogonial quantity in human prepubertal testicular tissue collected for fertility preservation prior to potentially sterilizing therapy. Hum Reprod. 2018. PMID: 30052981. doi:10.1093/humrep/dey240
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。